SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) saw unusually large options trading activity on Thursday. Stock investors acquired 57,085 call options on the company. This is an increase of approximately 29% compared to the average daily volume of 44,315 call options.
Analyst Ratings Changes
Several brokerages recently commented on SLS. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.
Check Out Our Latest Report on SELLAS Life Sciences Group
SELLAS Life Sciences Group Stock Down 4.6%
Shares of SLS opened at $9.68 on Friday. The stock has a market cap of $1.95 billion, a PE ratio of -46.09 and a beta of 2.56. SELLAS Life Sciences Group has a 12-month low of $1.39 and a 12-month high of $15.88. The business has a 50-day simple moving average of $12.16 and a two-hundred day simple moving average of $8.56.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).
Hedge Funds Weigh In On SELLAS Life Sciences Group
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Dagco Inc. raised its holdings in SELLAS Life Sciences Group by 8.4% during the 3rd quarter. Dagco Inc. now owns 1,336,449 shares of the company’s stock worth $16,452,000 after purchasing an additional 104,016 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of SELLAS Life Sciences Group by 535.7% in the 1st quarter. Bank of America Corp DE now owns 641,683 shares of the company’s stock valued at $2,714,000 after purchasing an additional 540,748 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of SELLAS Life Sciences Group by 73.2% in the 2nd quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock valued at $8,816,000 after purchasing an additional 252,531 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of SELLAS Life Sciences Group in the 2nd quarter valued at $7,823,000. Finally, Tidal Investments LLC increased its position in shares of SELLAS Life Sciences Group by 43.1% during the second quarter. Tidal Investments LLC now owns 128,761 shares of the company’s stock worth $1,901,000 after buying an additional 38,754 shares during the period. 17.38% of the stock is owned by institutional investors and hedge funds.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies. The company’s research and development programs are centered on treatments designed to stimulate or restore the immune system’s ability to recognize and attack cancer cells, as well as targeted therapies for hematologic malignancies.
SELLAS’ lead product candidate is galinpepimut-S (GPS), a multi-peptide immunotherapeutic targeting Wilms’ tumor 1 (WT1), a protein expressed in multiple types of cancer.
Recommended Stories
- Five stocks we like better than SELLAS Life Sciences Group
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
- The Factories Behind AI Servers Just Raised Their Outlooks—3 Contract Manufacturers to Watch
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
